In Phase 3 studies, more patients receiving Mounjaro 5 mg (3%), 10 mg (5.4%), and 15 mg (6.6%) discontinued treatment due to gastrointestinal (digestive tract) side effects than patients receiving placebo (0.4%)
Its name refers to the mechanism of action inspired by the natural signaling of the GLP-1 hormone (glucagon-like peptide-1) , which in the body helps send satiety signals to the brain after meals
In the SURMOUNT-2 trial (NCT04657003), tirzepatide treatment led to clinically meaningful bodyweight reduction versus placebo among participants living with obesity or overweight and T2D [10]
No one knows the extent of this issue or even whether it is an issue, Jones told Verywell
Nrrelund H, Nair KS, Nielsen S, Frystyk J, Ivarsen P, Jrgensen JOL, Christiansen JS, Mller N